Skip to main content

Regeneron Pharmaceuticals Lynozyfic revenue

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

Lynozyfic revenue at Regeneron Pharmaceuticals came to $19.0M for the quarter to 30 Sep 2026.

As Regeneron Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$0Mar 2025$0Jun 2025$800,000Sep 2025$11.2MMar 2026$16.5MJun 2026$19.0MSep 2026
Regeneron Pharmaceuticals Lynozyfic revenue, every reported period
Period endingLynozyfic revenueChange on a yearFiled
30 Sep 2026$19.0M—30 Oct 2026
30 Jun 2026$16.5M—30 Jul 2026
31 Mar 2026$11.2M—29 Apr 2026
30 Sep 2025$800,000—28 Oct 2025
30 Jun 2025$0—1 Aug 2025
31 Mar 2025$0—29 Apr 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Regeneron Pharmaceuticals: Collaboration revenue · Net product sales · Libtayo revenue · EYLEA HD And EYLEA revenue · EYLEA HD revenue · EYLEA revenue · Praluent revenue · Evkeeza revenue · financial statements

Every KPI and segment of REGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.